Latest News for: neurogenic

Edit

Statement of Changes in Beneficial Ownership (Form 4) (Neurogene Inc)

Public Technologies 17 Mar 2026
) FORM 4. Check this box if no longer subject to Section 16 ... See Instruction 1(b) ... Washington, D.C ... Neurogene Inc ... C/O NEUROGENE INC., 535 W 24TH STREET, 5TH FLOOR 3 ... C/O NEUROGENE INC ... The reporting person undertakes to provide Neurogene Inc ... Neurogene Inc.
Edit

Notice of Proposed Sale of Securities (Form 144) (Neurogene Inc)

Public Technologies 13 Mar 2026
). The text version of this document is not available ... Disclaimer. Neurogene Inc.
Edit

Neurogene to Participate in Stifel 2026 Virtual CNS Forum

The Eagle-Tribune 11 Mar 2026
NEW YORK--(BUSINESS WIRE)--Mar 11, 2026-- ... .
Edit

Loss of function of the chromatin remodeling gene INO80D leads to neurogenic features of schizophrenia

PNAS 05 Mar 2026
.
Edit

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The Galveston Daily News 04 Mar 2026
NEW YORK--(BUSINESS WIRE)--Mar 3, 2026-- ....
Edit

Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome

Business Wire 27 Feb 2026
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq ... The Breakthrough Therapy designation was based on the F .
Edit

Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome (Form 8-K) (Neurogene Inc)

Public Technologies 26 Feb 2026
) Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome ... NEW YORK - February 26, 2026 - Neurogene Inc ... About Neurogene. Neurogene (NASDAQ ... For more information, visit neurogene.com or follow on LinkedIn.
Edit

Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome (Neurogene Inc)

Public Technologies 26 Feb 2026
26, 2026-- Neurogene Inc ... NGN-401 is being evaluated as a one-time treatment for Rett syndrome and is designed to deliver the full-length human MECP2 gene under the control of Neurogene's proprietary EXACT™ transgene regulation technology.
Edit

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The Galveston Daily News 05 Feb 2026
NEW YORK--(BUSINESS WIRE)--Feb 4, 2026-- ....
Edit

Neurogene to Participate in Upcoming Investor Conferences

The Galveston Daily News 05 Feb 2026
NEW YORK--(BUSINESS WIRE)--Feb 5, 2026-- ....
Edit

Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Neurogene Inc)

Public Technologies 04 Feb 2026
4, 2026-- Neurogene Inc ... The Inducement Grant was granted as an inducement material to this individual entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4) ... About Neurogene ... [email protected].
Edit

Neurogenic Orthostatic Hypotension (nOH) Global Clinical Trials Market Review 2025: Region, Country (G7 & E7), ...

Nasdaq Globe Newswire 19 Jan 2026
This aids strategic investment decisions and optimizing strategies in the global Neurogenic Orthostatic Hypotension (nOH) landscape.
Edit

Neurogene 2026 JP Morgan Presentation (Neurogene Inc)

Public Technologies 14 Jan 2026
) EVERY BREAKTHROUGH BEGINS WITH BELIEF. 44th Annual J. P. Morgan Healthcare Conference January 2026. Rachel McMinn, Ph.D ... OUR MISSION ... OUR APPROACH ... 3 ... Neurogene is Positioned for Significant Value Inflection with Multiple Catalysts in 2026. 4 ... Neurogene Inc.
Edit

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene ...

The Galveston Daily News 12 Jan 2026
NEW YORK--(BUSINESS WIRE)--Jan 12, 2026-- ....
Edit

Neurogene Corporate Presentation January 2026 (Neurogene Inc)

Public Technologies 12 Jan 2026
) EVERY BREAKTHROUGH BEGINS WITH BELIEF. Corporate Presentation. January 2026. OUR MISSION ... OUR APPROACH. Biology-first design ... 3 ... Upcoming Milestones ... Neurogene is Positioned for Significant Value Inflection with Multiple Catalysts in 2026. 4 ... Neurogene Inc.

Article Search

tools
×
×
×
×